BioSpace News Archive

Vector Laboratories a leader in the development and manufacture of labeling and detection reagents for biomedical research, announced today the availability of a new guide for the growing field of immunofluorescence (IF).

Aurinia Pharmaceuticals announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).

Varex Imaging today announced that it will report financial results for the fourth quarter and fiscal year 2017 following the close of regular trading on Thursday, November 9, 2017.

Spero plans for a rapid development approach with SPR994.

Shionogi announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C.

The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development activities.

ANGLE plc, a world-leading liquid biopsy company, announces that its AGM will be held at 2:00pm on Tuesday 31 October 2017 at ANGLE plc, 10 Nugent Road, the Surrey Research Park, Guildford, GU2 7AF.

Management will host a conference call at 5:00 p.m. Eastern Time on November 1st to discuss the results of the third quarter.

Up to 140 patients will be enrolled in the INSIGHT trial at up to 20 U.S. and international centers.

ThromboGenics issues a business update for the three-month period ending 30 September 2017.